TCL1 family AKT coactivator BGenealiases: SYN-1 · TML1
Q-omics provides the consensus-scored TCL1B profile across patient tissues and cancer cell-line models. TCL1B expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TCL1B is differentially expressed in 7, with the highest sampling consensus in KIRP. Additionally, TCL1B RNA expression shows 9,583 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRP, and TGCT as cancer lineages where TCL1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCL1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCL1B survival associations across molecular data types. TCL1B RNA expression shows survival associations in the most cancer types (16), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCL1B RNA expression–survival associations across cancer types. High TCL1B expression shows unfavorable associations in UVM, CESC, READ and COAD, but favorable associations in UCS and ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TCL1B RNA expression.
This table summarizes TCL1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for TCL1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCL1B shows lower tumor expression in KIRP, KIRC, THCA and KICH and higher tumor expression in BRCA and HNSC. The KIRP box plot shows higher TCL1B RNA expression in normal versus tumor tissue (log2 FC = −0.088, t-test p < 0.001).
This table shows molecular features associated with TCL1B in patient tissues and cancer cell lines. In patient samples, TCL1B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TCL1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
